It sued, and after seven years it won. Prevagen is made by another company; it appears here only because its memory promise went all the way through a federal court. It has no link to MemoHoney.
In 2017 the FTC and New York’s Attorney General went after ads saying Prevagen “improves memory within 90 days”. They argued there was no evidence its active protein even reaches the brain, and that in the company’s own placebo trial, users did no better than chance would explain on nine separate tasks (FTC, Prevagen complaint (business blog)).
A federal court in New York ruled after a jury trial, and in December 2024 the FTC announced that Quincy Bioscience must drop its misleading pitch to people worried about memory loss (FTC, Statement on win against Prevagen makers). The FTC’s rule of thumb is simple: a health claim needs reliable scientific evidence, usually human trials of the same dose and formula, and customer stories never count as proof (FTC, Health Products Compliance Guidance).